Ann Neurol

1. PIEHL F, Alping P, Virtanen S, Englund S, et al
   COMBAT-MS: A Population-Based Observational Cohort Study Addressing the Benefit-Risk Balance of Multiple Sclerosis Therapies Compared with Rituximab.
   Ann Neurol. 2024 Jun 25. doi: 10.1002/ana.27012.
   

   >> Share

   
   

   
   J Neurol

2. LAL AP, Foong YC, Sanfilippo PG, Spelman T, et al
   A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic.
   J Neurol. 2024 Jun 27. doi: 10.1007/s00415-024-12518.
   

   >> Share

   
   
3. NOTEBOOM S, Seiler M, Chien C, Rane RP, et al
   Evaluation of machine learning-based classification of clinical impairment and prediction of clinical worsening in multiple sclerosis.
   J Neurol. 2024 Jun 23. doi: 10.1007/s00415-024-12507.
   

   >> Share

   
   

   
   Magn Reson Med

4. TOURELL M, Jin J, Bachrata B, Stewart A, et al
   Three-dimensional EPI with shot-selective CAIPIRIHANA for rapid high-resolution quantitative susceptibility mapping at 3 T.
   Magn Reson Med. 2024;92:997-1010.
   

   >> Share

   
   

   
   Mult Scler

5. MOROZUMI T, Preziosa P, Meani A, Pessina G, et al
   Brain and cervical spinal cord MRI correlates of sensorimotor impairment in patients with multiple sclerosis.
   Mult Scler. 2024 Jun 24:13524585241260145. doi: 10.1177/13524585241260145.
   

   >> Share

   
   
6. MALLUCCI G, Monti MC, Ponzio M, Borrelli P, et al
   Impact of multiple sclerosis comorbidities on quality of life and job activity.
   Mult Scler. 2024 Jun 24:13524585241260550. doi: 10.1177/13524585241260550.
   

   >> Share

   
   
7. SCARAMOZZA M, Chiesa PA, Zajac L, Sun Z, et al
   Konectom cognitive processing speed test enables reliable remote, unsupervised cognitive assessment in people with multiple sclerosis: Exploring the use of substitution time as a novel digital outcome measure.
   Mult Scler. 2024 Jun 24:13524585241259650. doi: 10.1177/13524585241259650.
   

   >> Share

   
   
8. MAGYARI M
   All women with multiple sclerosis should start hormone replacement therapy at menopause unless contraindicated: No.
   Mult Scler. 2024 Jun 22:13524585241254987. doi: 10.1177/13524585241254987.
   

   >> Share

   
   
9. PETHERAM K, Dobson R
   All women with multiple sclerosis should start hormone replacement therapy at menopause unless contraindicated: Commentary.
   Mult Scler. 2024 Jun 22:13524585241254989. doi: 10.1177/13524585241254989.
   

   >> Share

   
   

   
   Neurol Clin Pract

10. WOLF AB, Corboy JR
    Escalation to Anti-CD20 Treatment for Multiple Sclerosis Following Natalizumab-Associated Progressive Multifocal Leukoencephalopathy.
    Neurol Clin Pract. 2024;14:e200330.
    

    >> Share

    
    

    
    Rev Neurol

11. FERNANDEZ O, Montalban X, Aguera E, Aladro Y, et al
    [XVI Post-ECTRIMS Meeting: review of the new developments presented at the 2023 ECTRIMS Congress (I)].
    Rev Neurol. 2024;79:21-29.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share